Discontinue BASAGLAR, monitor and treat if indicated. Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur.Instruct patients to check insulin labels before injection. Medication Errors: Accidental mix-ups between insulin products can occur.Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity and in patients with renal or hepatic impairment and hypoglycemia unawareness. Hypoglycemia: May be life-threatening.Hyper- or hypoglycemia with changes in insulin regimen: Carry out under close medical supervision.Never share a BASAGLAR KwikPen between patients, even if the needle is changed.Hypersensitivity to BASAGLAR or one of its excipients. (2.1) -DOSAGE FORMS AND STRENGTHS- Injection: 100 units/mL (U-100) in 3 mL prefilled BASAGLAR ® KwikPen ® delivery device. Do not dilute or mix with any other insulin or solution.Closely monitor glucose when converting to BASAGLAR and during initial weeks thereafter.Rotate injection sites to reduce the risk of lipodystrophy.Administer subcutaneously once daily at any time of day, but at the same time every day. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, prior insulin use.(1) Limitations of Use: Not recommended for treating diabetic ketoacidosis. Approval: 2000 - INDICATIONS AND USAGE - BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. See full prescribing information for BASAGLAR BASAGLAR (insulin glargine injection), for subcutaneous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BASAGLAR safely and effectively.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |